ANAPTYSBIO, INCANABEarnings & Financial Report
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for inflammatory diseases, immuno-oncology indications, and rare disease conditions. It primarily serves the U.S. market, advancing its innovative product candidate pipeline to address unmet medical needs via rigorous research and clinical development.
Revenue
$7.2M
Gross Profit
N/A
Operating Profit
$-42.2M
Net Profit
$-43.9M
Gross Margin
N/A
Operating Margin
-587.8%
Net Margin
-612.0%
YoY Growth
422.5%
EPS
$-1.64
ANAPTYSBIO, INC Q1 FY2024 Financial Summary
ANAPTYSBIO, INC reported revenue of $7.2M (up 422.5% YoY) for Q1 FY2024, with a net profit of $-43.9M (up 0.7% YoY) (-612.0% margin).
Key Financial Metrics
| Total Revenue | $7.2M |
|---|---|
| Net Profit | $-43.9M |
| Gross Margin | N/A |
| Operating Margin | -587.8% |
| Report Period | Q1 FY2024 |
ANAPTYSBIO, INC Annual Revenue by Year
ANAPTYSBIO, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $234.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $234.6M |
| 2024 | $91.3M |
| 2023 | $17.2M |
| 2022 | $10.3M |
ANAPTYSBIO, INC Quarterly Revenue & Net Profit History
ANAPTYSBIO, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $108.2M | +151.1% | $49.6M | 45.8% |
| Q3 FY2025 | $76.3M | +154.3% | $15.1M | 19.8% |
| Q2 FY2025 | $22.3M | +102.9% | $-38.6M | -173.5% |
| Q1 FY2025 | $27.8M | +286.8% | $-39.3M | -141.6% |
| Q4 FY2024 | $43.1M | +378.8% | $-21.8M | -50.5% |
| Q3 FY2024 | $30.0M | +804.7% | $-32.9M | -109.4% |
| Q2 FY2024 | $11.0M | +217.1% | $-46.7M | -425.3% |
| Q1 FY2024 | $7.2M | +422.5% | $-43.9M | -612.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.2M | $11.0M | $30.0M | $43.1M | $27.8M | $22.3M | $76.3M | $108.2M |
| YoY Growth | 422.5% | 217.1% | 804.7% | 378.8% | 286.8% | 102.9% | 154.3% | 151.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $405.8M | $427.4M | $493.4M | $483.8M | $422.1M | $335.3M | $353.1M | $364.4M |
| Liabilities | $358.1M | $417.5M | $409.1M | $413.0M | $388.0M | $380.0M | $382.5M | $327.2M |
| Equity | $47.8M | $9.9M | $84.4M | $70.9M | $34.0M | $-44.7M | $-29.4M | $37.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.3M | $-21.3M | $-10.1M | $-66.7M | $-10.7M | $-40.2M | $-27.4M | $98.0M |